IRINOTECAN+CISPLATIN	0.2809241723746194	None
CISPLATIN+RAMUCIRUMAB	0.2809241723746194	None
MITOMYCIN+CISPLATIN	0.2809241723746194	None
VINCRISTINE+CISPLATIN	0.2809241723746194	None
CISPLATIN+AFATINIB	0.2809241723746194	None
CISPLATIN+ALECTINIB	0.2809241723746194	None
CISPLATIN+ERLOTINIB	0.2809241723746194	None
CISPLATIN+OLMUTINIB	0.2809241723746194	None
TOPOTECAN+CISPLATIN	0.2809241723746194	The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.
GEMCITABINE+CISPLATIN	0.2809241723746194	None
DOCETAXEL+CISPLATIN	0.2809241723746194	Cisplatin may increase the myelosuppressive activities of Docetaxel.
GEFITINIB+CISPLATIN	0.2809241723746194	None
PORFIMER+CISPLATIN	0.2809241723746194	None
DOXORUBICIN+CISPLATIN	0.2809241723746194	Cisplatin may increase the nephrotoxic activities of Doxorubicin.
PEMETREXED+CISPLATIN	0.2809241723746194	None
OSIMERTINIB+CISPLATIN	0.2809241723746194	None
BRIGATINIB+CISPLATIN	0.2809241723746194	None
CISPLATIN+CRIZOTINIB	0.2809241723746194	None
ETOPOSIDE+CISPLATIN	0.2809241723746194	None
METHOTREXATE+CISPLATIN	0.2809241723746194	None
VINORELBINE+CISPLATIN	0.2809241723746194	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.
BEVACIZUMAB+CISPLATIN	0.2809241723746194	Bevacizumab may increase the cardiotoxic activities of Cisplatin.
ICOTINIB+CISPLATIN	0.2809241723746194	None
ETOPOSIDE+OSIMERTINIB	-0.0	The serum concentration of Etoposide can be increased when it is combined with Osimertinib.
GEFITINIB+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.
GEFITINIB+CRIZOTINIB	-0.0	The metabolism of Gefitinib can be decreased when combined with Crizotinib.
ICOTINIB+ERLOTINIB	-0.0	None
GEFITINIB+BRIGATINIB	-0.0	None
GEFITINIB+ALECTINIB	-0.0	None
GEFITINIB+AFATINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Gefitinib.
ETOPOSIDE+RAMUCIRUMAB	-0.0	None
ETOPOSIDE+PEMETREXED	-0.0	None
ICOTINIB+NINTEDANIB	-0.0	None
ETOPOSIDE+OLMUTINIB	-0.0	None
ICOTINIB+RAMUCIRUMAB	-0.0	None
ETOPOSIDE+NINTEDANIB	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Etoposide.
ETOPOSIDE+METHOTREXATE	-0.0	None
ETOPOSIDE+IRINOTECAN	-0.0	None
ETOPOSIDE+ICOTINIB	-0.0	None
ETOPOSIDE+ERLOTINIB	-0.0	None
ETOPOSIDE+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Etoposide.
IRINOTECAN+AFATINIB	-0.0	None
IRINOTECAN+ALECTINIB	-0.0	None
ETOPOSIDE+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.
ETOPOSIDE+CRIZOTINIB	-0.0	The metabolism of Etoposide can be decreased when combined with Crizotinib.
GEFITINIB+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Gefitinib.
GEMCITABINE+DOXORUBICIN	-0.0	None
GEFITINIB+ERLOTINIB	-0.0	None
GEMCITABINE+METHOTREXATE	-0.0	None
GEMCITABINE+CARBOPLATIN	-0.0	None
GEMCITABINE+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Gemcitabine.
GEFITINIB+VINORELBINE	-0.0	Gefitinib may increase the neutropenic activities of Vinorelbine.
GEMCITABINE+ETOPOSIDE	-0.0	None
GEFITINIB+VINCRISTINE	-0.0	The excretion of Vincristine can be decreased when combined with Gefitinib.
GEFITINIB+RAMUCIRUMAB	-0.0	None
GEFITINIB+PORFIMER	-0.0	None
GEFITINIB+PEMETREXED	-0.0	None
GEFITINIB+OSIMERTINIB	-0.0	The serum concentration of Gefitinib can be increased when it is combined with Osimertinib.
GEMCITABINE+IRINOTECAN	-0.0	None
GEFITINIB+OLMUTINIB	-0.0	None
GEMCITABINE+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.
GEFITINIB+NINTEDANIB	-0.0	None
GEMCITABINE+PEMETREXED	-0.0	None
ETOPOSIDE+BRIGATINIB	-0.0	None
GEMCITABINE+RAMUCIRUMAB	-0.0	None
ICOTINIB+AFATINIB	-0.0	None
GEFITINIB+MITOMYCIN	-0.0	None
GEFITINIB+METHOTREXATE	-0.0	None
GEFITINIB+IRINOTECAN	-0.0	None
GEFITINIB+ICOTINIB	-0.0	None
ICOTINIB+ALECTINIB	-0.0	None
GEFITINIB+ETOPOSIDE	-0.0	None
VINORELBINE+RAMUCIRUMAB	-0.0	None
ETOPOSIDE+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Etoposide.
CARBOPLATIN+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Carboplatin.
BRIGATINIB+PEMETREXED	-0.0	None
BRIGATINIB+NINTEDANIB	-0.0	None
BRIGATINIB+METHOTREXATE	-0.0	None
BRIGATINIB+ERLOTINIB	-0.0	None
BRIGATINIB+DOXORUBICIN	-0.0	None
BRIGATINIB+BEVACIZUMAB	-0.0	None
BRIGATINIB+ALECTINIB	-0.0	None
BRIGATINIB+AFATINIB	-0.0	None
BEVACIZUMAB+RAMUCIRUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Ramucirumab.
BEVACIZUMAB+PEMETREXED	-0.0	Bevacizumab may increase the cardiotoxic activities of Pemetrexed.
BEVACIZUMAB+OLMUTINIB	-0.0	None
BEVACIZUMAB+METHOTREXATE	-0.0	Bevacizumab may increase the cardiotoxic activities of Methotrexate.
BEVACIZUMAB+ICOTINIB	-0.0	None
BEVACIZUMAB+ERLOTINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Erlotinib.
BEVACIZUMAB+DOXORUBICIN	-0.0	Bevacizumab may increase the cardiotoxic activities of Doxorubicin.
BEVACIZUMAB+CRIZOTINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Crizotinib.
BEVACIZUMAB+ALECTINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Alectinib.
BEVACIZUMAB+AFATINIB	-0.0	Bevacizumab may increase the cardiotoxic activities of Afatinib.
ALECTINIB+RAMUCIRUMAB	-0.0	None
ALECTINIB+NINTEDANIB	-0.0	None
ALECTINIB+ERLOTINIB	-0.0	None
ALECTINIB+AFATINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Alectinib.
AFATINIB+RAMUCIRUMAB	-0.0	None
AFATINIB+NINTEDANIB	-0.0	None
AFATINIB+ERLOTINIB	-0.0	None
BRIGATINIB+RAMUCIRUMAB	-0.0	None
CARBOPLATIN+PEMETREXED	-0.0	None
ETOPOSIDE+ALECTINIB	-0.0	None
CRIZOTINIB+NINTEDANIB	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Crizotinib.
ETOPOSIDE+AFATINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Etoposide.
DOXORUBICIN+RAMUCIRUMAB	-0.0	None
DOXORUBICIN+PEMETREXED	-0.0	None
DOXORUBICIN+OLMUTINIB	-0.0	None
IRINOTECAN+BEVACIZUMAB	-0.0	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
DOXORUBICIN+METHOTREXATE	-0.0	None
DOXORUBICIN+ICOTINIB	-0.0	None
DOXORUBICIN+ERLOTINIB	-0.0	None
DOXORUBICIN+CRIZOTINIB	-0.0	The metabolism of Doxorubicin can be decreased when combined with Crizotinib.
DOXORUBICIN+CRIZOTINIB	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Crizotinib.
DOXORUBICIN+ALECTINIB	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Alectinib.
DOXORUBICIN+AFATINIB	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Afatinib.
DOXORUBICIN+AFATINIB	-0.0	The serum concentration of Afatinib can be decreased when it is combined with Doxorubicin.
DOCETAXEL+RAMUCIRUMAB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.
DOCETAXEL+PEMETREXED	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.
DOCETAXEL+OLMUTINIB	-0.0	None
DOCETAXEL+NINTEDANIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Nintedanib.
DOCETAXEL+METHOTREXATE	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.
DOCETAXEL+ICOTINIB	-0.0	None
DOCETAXEL+ERLOTINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.
DOCETAXEL+DOXORUBICIN	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.
DOCETAXEL+DOXORUBICIN	-0.0	The metabolism of Doxorubicin can be decreased when combined with Docetaxel.
DOCETAXEL+CRIZOTINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.
DOCETAXEL+BRIGATINIB	-0.0	None
DOCETAXEL+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Docetaxel.
DOCETAXEL+ALECTINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Alectinib.
DOCETAXEL+AFATINIB	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.
CRIZOTINIB+RAMUCIRUMAB	-0.0	None
DOXORUBICIN+NINTEDANIB	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Doxorubicin.
IRINOTECAN+DOXORUBICIN	-0.0	The metabolism of Irinotecan can be decreased when combined with Doxorubicin.
IRINOTECAN+BRIGATINIB	-0.0	None
PEMETREXED+ICOTINIB	-0.0	None
VINCRISTINE+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Vincristine.
VINCRISTINE+ALECTINIB	-0.0	The excretion of Vincristine can be decreased when combined with Alectinib.
VINCRISTINE+AFATINIB	-0.0	The serum concentration of Afatinib can be decreased when it is combined with Vincristine.
VINCRISTINE+AFATINIB	-0.0	The excretion of Vincristine can be decreased when combined with Afatinib.
TOPOTECAN+VINCRISTINE	-0.0	The serum concentration of Topotecan can be increased when it is combined with Vincristine.
TOPOTECAN+RAMUCIRUMAB	-0.0	None
TOPOTECAN+PEMETREXED	-0.0	None
TOPOTECAN+METHOTREXATE	-0.0	None
TOPOTECAN+IRINOTECAN	-0.0	None
TOPOTECAN+DOXORUBICIN	-0.0	The serum concentration of Topotecan can be increased when it is combined with Doxorubicin.
TOPOTECAN+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.
TOPOTECAN+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Topotecan.
RAMUCIRUMAB+NINTEDANIB	-0.0	None
RAMUCIRUMAB+ERLOTINIB	-0.0	None
PORFIMER+RAMUCIRUMAB	-0.0	None
PORFIMER+PEMETREXED	-0.0	None
PORFIMER+NINTEDANIB	-0.0	None
PORFIMER+METHOTREXATE	-0.0	None
PORFIMER+IRINOTECAN	-0.0	None
PORFIMER+ETOPOSIDE	-0.0	None
PORFIMER+ERLOTINIB	-0.0	None
PORFIMER+DOXORUBICIN	-0.0	None
PORFIMER+DOCETAXEL	-0.0	None
PORFIMER+BEVACIZUMAB	-0.0	None
PORFIMER+ALECTINIB	-0.0	None
PORFIMER+AFATINIB	-0.0	None
PEMETREXED+RAMUCIRUMAB	-0.0	None
PEMETREXED+OLMUTINIB	-0.0	None
VINCRISTINE+BRIGATINIB	-0.0	None
VINCRISTINE+CARBOPLATIN	-0.0	None
VINCRISTINE+CRIZOTINIB	-0.0	The metabolism of Vincristine can be decreased when combined with Crizotinib.
VINCRISTINE+RAMUCIRUMAB	-0.0	None
VINORELBINE+NINTEDANIB	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Vinorelbine.
VINORELBINE+METHOTREXATE	-0.0	None
VINORELBINE+IRINOTECAN	-0.0	None
VINORELBINE+GEMCITABINE	-0.0	None
VINORELBINE+ETOPOSIDE	-0.0	None
VINORELBINE+ERLOTINIB	-0.0	None
VINORELBINE+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Vinorelbine.
VINORELBINE+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.
VINORELBINE+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Vinorelbine.
VINORELBINE+ALECTINIB	-0.0	None
VINORELBINE+AFATINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Vinorelbine.
VINCRISTINE+VINORELBINE	-0.0	The excretion of Vincristine can be decreased when combined with Vinorelbine.
VINCRISTINE+PORFIMER	-0.0	None
VINCRISTINE+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.
VINCRISTINE+PEMETREXED	-0.0	None
VINCRISTINE+OSIMERTINIB	-0.0	The serum concentration of Vincristine can be increased when it is combined with Osimertinib.
VINCRISTINE+OLMUTINIB	-0.0	None
VINCRISTINE+NINTEDANIB	-0.0	The serum concentration of Nintedanib can be increased when it is combined with Vincristine.
VINCRISTINE+MITOMYCIN	-0.0	The risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.
VINCRISTINE+MITOMYCIN	-0.0	The excretion of Vincristine can be decreased when combined with Mitomycin.
VINCRISTINE+METHOTREXATE	-0.0	None
VINCRISTINE+IRINOTECAN	-0.0	None
VINCRISTINE+ICOTINIB	-0.0	None
VINCRISTINE+GEMCITABINE	-0.0	None
VINCRISTINE+ETOPOSIDE	-0.0	The excretion of Vincristine can be decreased when combined with Etoposide.
VINCRISTINE+ERLOTINIB	-0.0	None
VINCRISTINE+DOXORUBICIN	-0.0	The serum concentration of Vincristine can be decreased when it is combined with Doxorubicin.
VINCRISTINE+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Vincristine.
PEMETREXED+NINTEDANIB	-0.0	None
PEMETREXED+ERLOTINIB	-0.0	None
IRINOTECAN+CRIZOTINIB	-0.0	The metabolism of Irinotecan can be decreased when combined with Crizotinib.
PEMETREXED+CRIZOTINIB	-0.0	None
MITOMYCIN+ERLOTINIB	-0.0	None
MITOMYCIN+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.
MITOMYCIN+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
MITOMYCIN+CRIZOTINIB	-0.0	None
MITOMYCIN+BRIGATINIB	-0.0	None
MITOMYCIN+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Mitomycin.
MITOMYCIN+ALECTINIB	-0.0	None
MITOMYCIN+AFATINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Mitomycin.
METHOTREXATE+RAMUCIRUMAB	-0.0	None
METHOTREXATE+PEMETREXED	-0.0	None
METHOTREXATE+OLMUTINIB	-0.0	None
METHOTREXATE+NINTEDANIB	-0.0	None
METHOTREXATE+ICOTINIB	-0.0	None
METHOTREXATE+ERLOTINIB	-0.0	None
METHOTREXATE+CRIZOTINIB	-0.0	None
METHOTREXATE+ALECTINIB	-0.0	None
METHOTREXATE+AFATINIB	-0.0	None
IRINOTECAN+RAMUCIRUMAB	-0.0	None
IRINOTECAN+PEMETREXED	-0.0	None
IRINOTECAN+OSIMERTINIB	-0.0	The serum concentration of Irinotecan can be increased when it is combined with Osimertinib.
IRINOTECAN+OLMUTINIB	-0.0	None
IRINOTECAN+NINTEDANIB	-0.0	None
IRINOTECAN+METHOTREXATE	-0.0	None
IRINOTECAN+ICOTINIB	-0.0	None
IRINOTECAN+ERLOTINIB	-0.0	None
VINORELBINE+PEMETREXED	-0.0	None
IRINOTECAN+DOCETAXEL	-0.0	The risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.
MITOMYCIN+ETOPOSIDE	-0.0	None
MITOMYCIN+GEMCITABINE	-0.0	None
MITOMYCIN+ICOTINIB	-0.0	None
OLMUTINIB+RAMUCIRUMAB	-0.0	None
PEMETREXED+ALECTINIB	-0.0	None
PEMETREXED+AFATINIB	-0.0	None
OSIMERTINIB+RAMUCIRUMAB	-0.0	None
OSIMERTINIB+PEMETREXED	-0.0	None
OSIMERTINIB+NINTEDANIB	-0.0	None
OSIMERTINIB+METHOTREXATE	-0.0	None
OSIMERTINIB+ERLOTINIB	-0.0	The serum concentration of Erlotinib can be increased when it is combined with Osimertinib.
OSIMERTINIB+DOXORUBICIN	-0.0	The serum concentration of Doxorubicin can be increased when it is combined with Osimertinib.
OSIMERTINIB+DOCETAXEL	-0.0	The serum concentration of Docetaxel can be increased when it is combined with Osimertinib.
OSIMERTINIB+BEVACIZUMAB	-0.0	Bevacizumab may increase the cardiotoxic activities of Osimertinib.
OSIMERTINIB+ALECTINIB	-0.0	None
OSIMERTINIB+AFATINIB	-0.0	None
OLMUTINIB+NINTEDANIB	-0.0	None
MITOMYCIN+IRINOTECAN	-0.0	None
OLMUTINIB+ERLOTINIB	-0.0	None
OLMUTINIB+ALECTINIB	-0.0	None
OLMUTINIB+AFATINIB	-0.0	None
NINTEDANIB+ERLOTINIB	-0.0	None
MITOMYCIN+VINORELBINE	-0.0	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mitomycin.
MITOMYCIN+RAMUCIRUMAB	-0.0	None
MITOMYCIN+PORFIMER	-0.0	None
MITOMYCIN+PEMETREXED	-0.0	None
MITOMYCIN+OSIMERTINIB	-0.0	None
MITOMYCIN+OLMUTINIB	-0.0	None
MITOMYCIN+NINTEDANIB	-0.0	None
MITOMYCIN+METHOTREXATE	-0.0	None
AFATINIB+CRIZOTINIB	-0.0	The serum concentration of Afatinib can be increased when it is combined with Crizotinib.
